Life Sciences: Beagles

Lord Patel Excerpts

Monday 9th February 2026 Lords Chamber

[Lord Hanson of Flint (Lab)]

I know how strongly my noble friend feels on this issue. I cannot promise him a Bill on this matter, but I can promise him a replacement strategy, which includes specific targets for reducing the use of dogs and, particularly, reducing their use in cardiovascular safety studies by at least 50% by 2030. The Government are also funding the national centre dealing with this issue to develop new, non-animal methods aimed at replacing dogs in regulatory testing. I hope that my noble friend will support the manifesto commitment to phase out use as soon as possible.

[Lord Patel (CB)]

My Lords, I support a reduction in the use of dogs in medical research. However, we have to understand that sometimes dogs are used because they have the same diseases as humans have; for instance, Duchenne muscular dystrophy, which is caused by a gene mutation called dystrophin which occurs in both dogs and humans, and kills children and dogs. Through a study of two retrievers who had the genes but were not affected, we learned the technique of silencing the gene—to the benefit of dogs and humans. Similarly, in other areas of cancer immunology, doing experiments to learn about both dogs and humans has enhanced their immunity. Lastly, insulin was discovered doing research on dogs, because dogs also get diabetes.

[Lord Hanson of Flint (Lab)]

My Lords, the noble Lord makes the point, which the Government accept, that animal testing is currently required where alternative, non-animal methods do not exist. We are also working with regulators to see how advances in technology can and will reduce the use, and phase out in some areas. We have a long-term ambition to phase out the use; it is in the manifesto. We have produced the document, but we recognise that, at the moment, medicine occasionally requires that use.